DMK Pharmaceuticals Corporation, along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on February 2, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, U.S. Compounding, Inc., Rhombus Pharmaceuticals Corporation, Biosyn, Inc. and Adamis Corporation, with its own case for administrative and procedural purposes. DMK Pharmaceuticals Corporation has been proposed as the lead debtor.